O
5.22
0.35 (7.19%)
| Previous Close | 4.87 |
| Open | 4.99 |
| Volume | 628,008 |
| Avg. Volume (3M) | 1,084,065 |
| Market Cap | 370,759,872 |
| Price / Book | 1.39 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Diluted EPS (TTM) | -1.83 |
| Total Debt/Equity (MRQ) | 3.85% |
| Current Ratio (MRQ) | 10.56 |
| Operating Cash Flow (TTM) | -112.66 M |
| Levered Free Cash Flow (TTM) | -67.10 M |
| Return on Assets (TTM) | -33.95% |
| Return on Equity (TTM) | -54.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Oric Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -4.0 |
| Average | 1.38 |
|
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.44% |
| % Held by Institutions | 103.72% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Column Group Llc | 31 Dec 2024 | 3,540,777 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (JP Morgan, 321.46%) | Buy |
| Median | 21.50 (311.88%) | |
| Low | 21.00 (HC Wainwright & Co., 302.30%) | Buy |
| Average | 21.50 (311.88%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Feb 2025 | 21.00 (302.30%) | Buy | 8.30 |
| 24 Feb 2025 | 21.00 (302.30%) | Buy | 7.56 | |
| JP Morgan | 26 Feb 2025 | 22.00 (321.46%) | Buy | 8.30 |
| 06 Feb 2025 | 21.00 (302.30%) | Buy | 12.54 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |